Stem Cell Research & Therapy · 2024 · 28 citations · 27 references
MedicineGeriatric MedicineAgingCell TherapyRegenerative MedicineCell-based TherapeuticsCell-based TherapiesFrailty AssessmentMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyPhysical FrailtyAge-related FrailtyPhysical Performance ImpairmentPlacebo-controlled Efficacy AssessmentPrimary Efficacy EndpointsStem Cell-based TherapyUmbilical Cord-derived CellsUmbilical Cord-derived Mesenchymal Stem CellsUmbilical Cord-derived Mesenchymal Stromal Cells
BACKGROUND: Mesenchymal stem cells (MSCs) hold a great promise for cell-based therapy in the field of regenerative medicine. In this study, we aimed to evaluate the safety and efficacy of intravenous infusion of human umbilical cord-derived MSCs (HUC-MSCs) in patients with aging frailty. METHODS: In this randomized, double-blind, placebo-controlled trial, participants diagnosed with aging frailty were randomly assigned to receive intravenous administrations of HUC-MSCs or placebo. All of serious adverse events and AEs were monitored to evaluate the safety of treatment during the 6-month follow-up. The primary efficacy endpoint was alteration of physical component scores (PCS) of SF-36 qualities of life at 6 months. The secondary outcomes including physical performance tests and pro-inflammatory cytokines, were also observed and compared at each follow-up visits. All evaluations were performed at 1 week, 1, 2, 3 and 6 months following the first intravenous infusion of HUC-MSCs. RESULTS: In the MSCs group, significant improvements in PCS of SF-36 were observed from first post-treatment visit and sustained throughout the follow-up period, with greater changes compared to the placebo group (p = 0.042). EQ-VAS scores of MSCs group improved significantly at 2 month (p = 0.023) and continued until the end of the 6-month visit (p = 0.002) in comparison to the placebo group. The timed up and go (TUG) physical performance test revealed significant group difference and showed continual enhancements over 6 months (p < 0.05). MSC transplantation improved the function of 4-m walking test (4MWT) compared with the placebo group with a decrease of 2.05 s at 6 months of follow-up (p = 0.21). The measurement of grip strength revealed group difference with MSCs group demonstrating better performance, particularly at 6 months (p = 0.002). Inflammatory cytokines (TNF-α, IL-17) exhibited declines in MSCs group at 6 months compared to the placebo group (p = 0.034 and 0.033, respectively). There was no difference of incidence of AEs between the two groups. CONCLUSION: Intravenous transplantation of HUC-MSCs is a safe and effective therapeutic approach on aging frailty. The positive outcomes observed in improving quality of life, physical performance, and reducing chronic inflammation, suggest that HUC-MSC therapy may be a promising potential treatment option for aging frailty. TRIAL REGISTRATION: Clinicaltrial.gov; NCT04314011; https://clinicaltrials.gov/ct2/show/NCT04314011 .
27
Frailty in Older Adults: Evidence for a Phenotype
Linda P. Fried, Catherine M. Tangen, Jeremy Walston et al. · The Journals of Gerontology Series A · 2001 · 24.5K citations · Full text
Critical Parameters for the Isolation of Mesenchymal Stem Cells from Umbilical Cord Blood
Karen Bieback, Susanne Kern, Harald Klüter et al. · Stem Cells · 2004 · 923 citations · Full text